Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
GLP-1 analogue
antidiabetic drug
clinical trial
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
27
01
2021
received:
06
11
2020
accepted:
09
02
2021
pubmed:
17
2
2021
medline:
10
7
2021
entrez:
16
2
2021
Statut:
ppublish
Résumé
This double-blind, randomized, single-site, crossover trial compared the injection-site experience with the starting doses of semaglutide and dulaglutide. Healthy subjects (aged 18-75 years; body mass index ≥ 25 kg/m
Identifiants
pubmed: 33591618
doi: 10.1111/dom.14349
pmc: PMC8251561
doi:
Substances chimiques
Hypoglycemic Agents
0
Immunoglobulin Fc Fragments
0
Recombinant Fusion Proteins
0
semaglutide
53AXN4NNHX
Glucagon-Like Peptides
62340-29-8
dulaglutide
WTT295HSY5
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1415-1419Subventions
Organisme : This trial was funded by Novo Nordisk A/S
Informations de copyright
© 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Diabetes Metab Syndr Obes. 2017 Sep 29;10:403-412
pubmed: 29033597
Diabetes Metab Syndr Obes. 2020 Feb 18;13:433-438
pubmed: 32110076
Diabetes Obes Metab. 2021 Jun;23(6):1415-1419
pubmed: 33591618
J Diabetes Sci Technol. 2015 Apr 21;9(5):1071-9
pubmed: 25901022
Diabetes Ther. 2020 Jun;11(6):1199-1216
pubmed: 32297119
Diabetes Obes Metab. 2014 Oct;16(10):971-6
pubmed: 24720741
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124
pubmed: 33298420
Pharmacotherapy. 2002 Sep;22(9):1105-9
pubmed: 12222545
Clin Pharm. 1987 Sep;6(9):725-7
pubmed: 3677570
Ann Emerg Med. 1996 Apr;27(4):485-9
pubmed: 8604867
Somatosens Mot Res. 2006 Mar-Jun;23(1-2):37-43
pubmed: 16846958
Pain. 2009 Jul;144(1-2):35-42
pubmed: 19356853